MedTrace Logo

A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets

NCT05868057 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-12-08

No results posted yet for this study

Summary

To assess the relative bioavailability of SHR7280 dry suspension and tablets in healthy subjects.

To assess the safety and tolerability of a single dose of SHR7280 dry suspension and tablets.

Conditions

  • Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction

Interventions

DRUG

SHR7280 tablets

SHR7280 tablets 1 time

DRUG

SHR7280 dry suspension

SHR7280 dry suspension 1 time

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-23
Primary Completion
2023-06-09
Completion
2023-10-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05868057 on ClinicalTrials.gov